Group 1 - The core point of the news is that Zhijiang Bio has seen a 5% increase in stock price, reaching 23.94 CNY per share, with a total market capitalization of 4.6 billion CNY [1] - Zhijiang Bio, established on April 18, 2005, specializes in the research, production, and sales of molecular diagnostic reagents and equipment, with 86.47% of its revenue coming from nucleic acid testing kits [1] - The company is located in Minhang District, Shanghai, and was listed on January 18, 2021 [1] Group 2 - Among the top circulating shareholders of Zhijiang Bio, Dazhong Fund's Dazhong Jingheng Mixed A (090019) holds 909,200 shares, unchanged from the previous period, representing 0.47% of circulating shares [2] - Dazhong Jingheng Mixed A has achieved a year-to-date return of 46.93%, ranking 1332 out of 8140 in its category [2] - The fund was established on June 15, 2012, and has a current scale of 694 million CNY, with a cumulative return of 393.36% since inception [2]

Core Viewpoint - Zhijiang Biotech experienced a decline of 5.03% on September 23, with a stock price of 22.86 CNY per share and a total market capitalization of 4.393 billion CNY [1] Company Overview - Zhijiang Biotech, established on April 18, 2005, and listed on January 18, 2021, is located in Minhang District, Shanghai. The company specializes in the research, production, and sales of molecular diagnostic reagents and equipment [1] - The revenue composition of the company includes 86.47% from nucleic acid testing kits, 11.99% from other products, and 1.54% from molecular diagnostic instruments [1] Shareholder Information - Among the top ten circulating shareholders of Zhijiang Biotech, a fund under Rongtong Fund holds 1.5 million shares, unchanged from the previous period, representing 0.78% of the circulating shares. The estimated floating loss today is approximately 1.815 million CNY [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) was established on December 25, 2014, with a current scale of 2.074 billion CNY. Year-to-date returns are 19.74%, ranking 4408 out of 8172 in its category, while the one-year return is 46.63%, ranking 3544 out of 7995 [2] Fund Manager Information - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has been in the position for 9 years and 31 days. The total asset scale of the fund is 5.629 billion CNY, with the best return during his tenure being 155.09% and the worst being -17.06% [3]

广发价值核心混合A（010377）成立日期2021年1月22日，最新规模35.16亿。今年以来收益68.54%，同 类排名147/8194；近一年收益114.67%，同类排名129/7963；成立以来亏损0.78%。 广发价值核心混合A（010377）基金经理为吴远怡。 截至发稿，吴远怡累计任职时间4年333天，现任基金资产总规模204.78亿元，任职期间最佳基金回报 113.46%， 任职期间最差基金回报-17.06%。 8月27日，之江生物跌5.13%，截至发稿，报25.71元/股，成交2.01亿元，换手率3.94%，总市值49.40亿 元。 资料显示，上海之江生物科技股份有限公司位于上海市闵行区陈行公路2168号9号楼，成立日期2005年4 月18日，上市日期2021年1月18日，公司主营业务涉及分子诊断试剂及仪器设备的研发、生产和销售。 主营业务收入构成为：核酸检测试剂盒82.71%，其它10.54%，分子诊断仪器5.00%，其他(补充)1.75%。 从之江生物十大流通股东角度 数据显示，广发基金旗下1只基金位居之江生物十大流通股东。广发价值核心混合A（010377）一季度 持有股数481.72万股， ...

8月26日，之江生物跌5%，截至发稿，报27.53元/股，成交1.62亿元，换手率3.01%，总市值52.90亿元。 资料显示，上海之江生物科技股份有限公司位于上海市闵行区陈行公路2168号9号楼，成立日期2005年4 月18日，上市日期2021年1月18日，公司主营业务涉及分子诊断试剂及仪器设备的研发、生产和销售。 主营业务收入构成为：核酸检测试剂盒82.71%，其它10.54%，分子诊断仪器5.00%，其他(补充)1.75%。 从之江生物十大流通股东角度 数据显示，大成基金旗下1只基金位居之江生物十大流通股东。大成景恒混合A（090019）一季度持有 股数90.92万股，持股数量与上期相比不变，占流通股的比例为0.47%。根据测算，今日浮亏损失约 131.83万元。 大成景恒混合A（090019）成立日期2012年6月15日，最新规模3.97亿。今年以来收益37.41%，同类排 名1284/8194；近一年收益103.51%，同类排名262/7962；成立以来收益361.38%。 大成景恒混合A（090019）基金经理为苏秉毅。 截至发稿，苏秉毅累计任职时间13年203天，现任基金资产总规模12.4亿元， ...

8月26日，之江生物跌5%，截至发稿，报27.53元/股，成交1.62亿元，换手率3.01%，总市值52.90亿元。 资料显示，上海之江生物科技股份有限公司位于上海市闵行区陈行公路2168号9号楼，成立日期2005年4 月18日，上市日期2021年1月18日，公司主营业务涉及分子诊断试剂及仪器设备的研发、生产和销售。 主营业务收入构成为：核酸检测试剂盒82.71%，其它10.54%，分子诊断仪器5.00%，其他(补充)1.75%。 从之江生物十大流通股东角度 截至发稿，万民远累计任职时间9年3天，现任基金资产总规模42.23亿元，任职期间最佳基金回报 163.77%， 任职期间最差基金回报-14.89%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，融通基金旗下1只基金位居之江生物十大流通股东。融通健康产业灵活配置混合A/B （000727）一季度减持20万股，持有股数150万股，占流通股的比例为0.78%。根据测算，今日浮亏损 失约21 ...